Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors
- PMID: 36400017
- DOI: 10.1016/j.ccell.2022.10.023
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors
Abstract
Brain tumors are notoriously difficult to treat. Three recent Cancer Cell articles aim to uncover novel druggable targets in IDH mutant gliomas, diffuse midline gliomas, and medulloblastomas, respectively, and show that these brain tumor types shift their metabolism to become reliant on de novo pyrimidine synthesis.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests K.R.K. is co-founder of Atish Technologies and serves on the Scientific Advisory Boards of NVision Imaging Technologies and Imaginostics. He holds patents related to imaging and leveraging cellular metabolism.
Comment on
-
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma.Cancer Cell. 2022 Dec 12;40(12):1488-1502.e7. doi: 10.1016/j.ccell.2022.10.009. Epub 2022 Nov 10. Cancer Cell. 2022. PMID: 36368321
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical